The act of traditional Chinese medicine is expected to be introduced this year J: improve the standardization of Chinese medicine industry 
 
 
Release date: 2015-03-06 13:35:28 
 
 
Source: China's news 

    On March 4 in the afternoon, the seventh "sound, responsibility" medical representatives and committee of CPPCC conferences held in Beijing. The delegates who attended bidding on drug and examination and approval, legislation, "orphan drug" of traditional Chinese medicine research and development and production, high configuration of licensed pharmacists and other medical attention topic, put forward many pertinent opinions and Suggestions.
 
    President of tianjin medical university, Chinese academy of engineering academician zhang bl is put forward, the method of traditional Chinese medicine with years of brewing is expected to be introduced this year, finishing need to work harder. , said zhang bl proprietary Chinese medicine industry in our country, the market share of three finished products of drugs has been close to 30%, but 2012, 2013, 2012, the number of traditional Chinese medicine (TCM) approved respectively is 37, 27, 24, respectively was approved by 6.0% of the total, 6.5%, 4.7%, the proportion is low. He suggested that eating drug safety administration to adjust and modify registration policy as soon as possible, to support the inheritance and innovation of traditional Chinese medicine (TCM).
 
    In addition, he also hopes to continue to conduct Chinese census, further attention to the protection of the endangered rare medicinal materials and sustainable development; Hope as soon as possible a non-prescription drugs to simplify the disposal of accreditation, promote the innovative development of non-prescription drugs; He suggested that health development planning commission to modify the prescription management way, to ensure easy access to paper or electronic prescription outpatient service patient, make voluntary decisions, prescription dispensing; Improve the drug approval charge threshold, hope to be able to use a third party to evaluate, government purchasing service way, promote efficiency of the review.
 
    Beijing health offer part combed the medicine of the NPC and CPPCC proposals and Suggestions.
 
    Sichuan koren group chairman liu's innovation: a clear definition of rare diseases, build system of orphan drug recognition; Many linkage formulate scientific incentive policy and industrial policy, speed up progress of orphan drug listed; Simplify examination and approval procedures for orphan drug review, formulate detailed rules for the implementation of orphan drug priority review; Establish a perfect system of rare diseases, into a serious illness insurance.
 
    Kahn bei group chairman Hu Jijiang: urged the CFDA modification instructions and labels, should be docked by laws and regulations; Hope stipulations on the management of the national development and reform commission issued as soon as possible low-cost medicine, suggested that drug pricing should be based on cost of volatility and reasonable profit properly; Suggested that the ministry of health issued as soon as possible the specific provision of basic drug use proportion.
 
    Tasly group chairman 闫希军 : hope to strengthen the review and implementation by the Chinese traditional medicine quality, strengthening the protection of Chinese herbal medicine resources; At present Chinese medicine evaluation experts subsidies, some will have to be borne by the enterprise, hope that relevant enterprises can suggest the Treasury reduce the financial burden on enterprises.
 
    Taizhou of jiangsu province pharmaceutical city secretary of the party working Liu Chunyun: improve the efficiency of the review, Suggestions to encourage innovation; Support drug research and development, production specialization, carry out intensive production is to promote research and development innovation; For cheap medicine practice the protective price system.
 
    Wan west pharmaceutical director ChangSunYaoZhi: legally intensify to support traditional Chinese medicine industry in China; To strengthen the protection of our country classic square disease proprietary Chinese medicine.
 
    Guangxi wuzhou zhongheng group co., LTD., chairman of Xu Shuqing: accelerate the standardization, modernization and internationalization, establish and improve the standardization of Chinese medicine system, establishing and perfecting the law system of traditional Chinese medicine, the practice of management modernization of traditional Chinese medicine industry.
 
    Saint pharmaceutical group chairman liu: drug problem is not in production and in circulation, want to do a good job of medicine circulation regulation.
 
    Talc pharmaceutical chairman Ren Wuxian: strengthen the encouragement mechanism of innovative drugs; Update as soon as possible in the next version of medicine health care directory, it is suggested that two years the longest once every three years to update the medical insurance directory; Suggest to cancel in drug bidding and sales to provide drug inspection report.